Challenges and opportunities to end tuberculosis in the COVID-19 era
- PMID: 33773121
- PMCID: PMC7988354
- DOI: 10.1016/S2213-2600(21)00161-2
Challenges and opportunities to end tuberculosis in the COVID-19 era
Conflict of interest statement
TW is supported by grants from the Wellcome Trust (209075/Z/17/Z and Joint Global Health Trials, MR/V004832/1), the Medical Research Council (MRC), Department for International Development, the Academy of Medical Sciences, and the Swedish Health Research Council. LEC is supported by grants from the European and Developing Countries Clinical Trial Partnership (EDCTP, DRIA2014-309), the MRC, the TB REACH Initiative of the Stop TB Partnership (STBP/TBREACH//GSA/W5-07), the Wellcome Trust (contract pending), and the Health Protection Research Unit for Emerging and Zoonotic Infections. PM is funded by the Wellcome Trust (206575/Z/17/Z). KAM works on projects funded with UK aid from the UK Government. SBS is supported by the National Institute for Health Research Global Health Research Unit on Lung Health and TB in Africa at the Liverpool School of Tropical Medicine (16/136/35) and the Foreign, Commonwealth and Development Office Research Programme Consortium Leaving no-one behind, transforming gendered pathways to health for TB (LIGHT PO8614). All authors declare no competing interests.
Figures
References
-
- The Stop TB Partnership 12 months of COVID-19 eliminated 12 years of progress in the global fight against tuberculosis. March 18, 2021. http://www.stoptb.org/news/stories/2021/ns21_011.html
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
